YMAB: Y-mAbs Therapeutics, Inc. Stock

by  •  • Comments Off on YMAB: Y-mAbs Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 175.70
Enterprise Value ($M) 115.39
Book Value ($M) 89.46
Book Value / Share 1.98
Price / Book 1.96
NCAV ($M) 67.29
NCAV / Share 1.49
Price / NCAV 2.61

Profitability (mra)
Return on Invested Capital (ROIC) -0.31
Return on Assets (ROA) -0.23
Return on Equity (ROE) -0.28

Liquidity (mrq)
Quick Ratio 4.35
Current Ratio 4.77

Balance Sheet (mrq) ($M)
Current Assets 90.45
Assets 112.61
Liabilities 23.16
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 87.69
Operating Income -25.11
Net Income -29.67
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -15.71
Cash from Investing 0.00
Cash from Financing 4.31

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13G Caligan Partners LP 5.20
11-14 13G/A Paradigm Biocapital Advisors LP 9.20 85.89
11-12 13G/A Vanguard Group Inc 4.56 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2025-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A
2025-03-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 39,030 132,528 29.45
2025-05-14 54,126 218,618 24.76
2025-05-13 45,099 310,098 14.54
2025-05-12 23,507 113,565 20.70

(click for more detail)

Similar Companies
XBIT – XBiotech Inc. XERS – Xeris Biopharma Holdings, Inc.
XLO – Xilio Therapeutics, Inc. ZVRA – Zevra Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io